Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemothe...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 14; p. 1307882
Main Authors: Lazar, Raluca, Fischbach, Cathie, Schott, Roland, Somme, Laura
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 27.03.2024
Subjects:
BRAF non-V600E mutations
immunotherapy
NSCLC
Oncology
PD-L1
targeted therapy
PD-L1
targeted therapy
BRAF non-V600E mutations
NSCLC
immunotherapy
ISSN:2234-943X, 2234-943X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemotherapy. Approximately 4% of NSCLC patients harbor BRAF mutations; the V600E mutation is the most common. Non-V600 mutations is an heterogeneous population and account for approximately 50% of BRAF -mutated NSCLC. BRAF mutations are classified into 3 functional classes based on their kinase activity and their signaling mechanism. The European Medicines Agency and the United States Food and Drug Administration have approved dabrafenib, an anti-BRAF tyrosine kinase inhibitor (TKI), in combination with trametinib, an anti-MEK TKI, for the treatment of patients with BRAF V600E-mutated metastatic NSCLC. The use of targeted therapies in NSCLC with BRAF non-V600E mutations remains controversial. There is a lack of guidelines regarding therapeutic options in non-V600E BRAF -mutated NSCLC. Herein, we presented 3 cases of NSCLC with BRAF non-V600E mutations and reviewed the current state of therapies for this particular population of lung cancer.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Anna Maria Carillo, Federico II University Hospital, Italy
Edited by: Pasquale Pisapia, University of Naples Federico II, Italy
Reviewed by: Andriani Charpidou, National and Kapodistrian University of Athens, Greece
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1307882